Clinical Trial Update: Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial studying pevonedistat with pembrolizumab for dMMR/MSI-H metastatic or locally advanced unresectable solid tumors; trial terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Neoplasm
• Unresectable Malignant Solid Neoplasm

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Pevonedistat (pevonedistat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-12-21